Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in China / NCT05388682
Recruiting Observational

Treatment of Patients With Takayasu Arteritis Complicated With Pulmonary Artery Involvement

NCT05388682 · tracked via the Priya Life Science China tracker
Sponsor
Chinese Pulmonary Vascular Disease Research Group
Phase
Observational
Started
2014-01-19
Last updated
2026-09-22

Condition(s) studied

Takayasu Arteritis With Pulmonary Artery InvolvementPercutaneous Transluminal Pulmonary AngioplastyPAH Targeted Medication

Investigational drug(s) / intervention(s)

Percutaneous transluminal pulmonary angioplasty

Percutaneous transluminal pulmonary angioplasty: Percutaneous transluminal pulmonary angioplasty

Study summary

1. Evaluate the effect of medical treatment and percutaneous transluminal pulmonary angioplasty on takayasu arteritis with pulmonary artery involvement
2. evaluate the efficacy of FAPI in predicting the activity and treatment efficacy of takayasu arteritis with pulmonary artery involvement

Eligibility

Sex
ALL
Min age
—
Max age
—
Healthy volunteers
No
Inclusion Criteria: * patients diagnosed with Takayasu arteries with pulmonary arteries involvement Exclusion Criteria: * Patients had pulmonary artery stenosis arising from CTEPH, fibrosing mediastinitis and congenital pulmonary artery stenosis

Primary outcome measure(s)

  • all cause death — 2014/1/1-2042/12/31
    all cause death
  • mean pulmonary arterial pressure change — 2014/1/1-2042/12/31
    change of mean pulmonary arterial pressure after treatment
  • pulmonary vascular resistance change — 2014/1/1-2042/12/31
    chagne of pulmonary vascular resistance after treatment
  • 6MWD change — 2014/1/1-2042/12/31
    change of six minute walk distance after treatment
  • peak VO2 change — 2014/1/1-2042/12/31
    change of peak oxygen consumption after treatment
  • NT-proBNP change — 2014/1/1-2042/12/31
    change of NT-proBNP after treatment
  • RV/LV change — 2014/1/1-2042/12/31
    change of right ventricular end-diastolic diameter versus laboratory left ventricular end-diastolic diameterafter treatment
  • CI change — 2014/1/1-2042/12/31
    change of cardiac index after treatment

Trial sites (1)

FacilityCityRegionStatus
Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College Beijing China Recruiting

More Chinese Pulmonary Vascular Disease Research Group trials in China

PAH-SDB: Sleep-Disordered Breathing and Outcomes in Pulmonary Arterial Hypertension Recruiting
Artificial Intelligence-assisted Evaluation of Pulmonary HYpertension Recruiting
Safety and Efficacy of Balloon Pulmonary Angioplasty in China Recruiting
the Application of Cardiopulmonary Exercise Testing in Assessment Outcome of Patients With Pulmonary Hypertension Recruiting
Prevalence, Phenotypes, Predictors and Prognostic Implication of Obstructive Sleep Apnea in Pulmonary Hypertension Recruiting

Other trials for the same condition

Clinical Features and Prognosis of Takayasu's Arteritis With Pulmonary Arteries Involvement Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05388682 on ClinicalTrials.gov ↗ ← All trials in China